CancerSeq™ FFPE tissues from AMSBIO are pre-screened tumor tissue samples for single nucleotide polymorphisms (SNP’s), insertions and deletions plus copy number variations (CNVs) using targeted Next Generation Sequencing to identify key mutations and mutational hotspots.
Cambridge, UK – 13 November 2024: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that the first patient has been dosed in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. This international trial is due to recruit up to 30 adult patients at clinical centres in the UK, Austria, Bulgaria, Poland and Spain. Initial data readouts are expected by the end of 2025.
30 October 2024 - Boehringer submitted a VAT refund claim to HMRC for £21,488,167 covering an initial six-year period. This amount is potentially a drop in the ocean compared to the NHS’s projected £19bn expenditure on medicines each year.
London 14th November 2024: Kadans Science Partner is excited to today announce the official opening of their new state-of-the-art laboratory building MAYDE, 5-10 Brandon Road.
Cambridge, UK, 12th November 2024: Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created role of Chief Scientific & Innovation Officer.
At Laverock we have an exciting opportunity for a talented and highly motivated Research Associate to join an exciting new business venture focused on applying the company’s proprietary gene silencing platform (GEiGS) to the development of novel human therapeutics. The GEiGS technology facilitates Stable, Tunable and Programmable silencing activity that differentiates it from alternative gene editing or gene regulation approaches, and specifically enables production of programmable, next-generation cell and gene therapies, addressing many current limitations.
